

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 6118)**

## **PROFIT WARNING**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of Austar Lifesciences Limited (“**Company**” and together with its subsidiaries, the “**Group**”) wishes to inform the shareholders of the Company and potential investors that, based on information currently available, the Group is expected to record a substantial reduction of approximately 80% to 95% in consolidated profits attributable to the shareholders of the Company for the year ending 31 December 2015, as compared with the corresponding period in 2014, mainly attributable to (i) prolonged execution time for certain projects undertaken by the Group during the period resulting in a decrease in revenue and a lowered gross profit margin as compared with the corresponding period in 2014; and (ii) certain projects with a relatively lower gross profit margin being undertaken by the Group during the period for the purpose of retaining customers.

As the period covered by this financial year has not yet ended, the information contained in this announcement is only based on the preliminary assessment of the information currently available to the Board, including the unaudited consolidated management accounts of the Group for the ten months ended 31 October 2015 and is not based on any figure or information which has been audited or reviewed by the Company’s auditors. Details of the Group’s financial information and performance will be disclosed in the Group’s annual results announcement for the year ending 31 December 2015.

**Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Austar Lifesciences Limited**  
**Ho Kwok Keung, Mars**  
*Chairman and Chief Executive Officer*

Hong Kong, 20 November 2015

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Raco Ivan Jordanov (alias Racho Jordanov).*